Vascular Considerations for Patients Receiving Amyloid Immunotherapy

Topic: Amyloid, tau and blood-test diagnosis

Abstract Amyloid-related imaging abnormalities (ARIA) in the form of edema/effusions (ARIA-E) or hemorrhagic lesions (ARIA-H) are the most impactful adverse event associated with anti-amyloid immunotherapy for Alzheimer disease. Most ARIA events are mild or silent, but a small subset can be severely symptomatic or fatal. The pathophysiologic mechanisms for ARIA appear centered around interactions of β-amyloid peptide (Aβ) with the cerebrovasculature as it transits from plaques to the perivascular space or through direct antibody-Aβ interactions after deposition in arterioles as cerebral amyloid angiopathy (CAA). The key role of the vasculature in generating ARIA creates challenges for vascular clinicians, including safety of immunotherapy for individuals with CAA markers, whether immunotherapy-treated patients can also receive anticoagulants or thrombolytics, and treatment of severe ARIA. Among key vascular that have emerged from clinical trial data and adverse event reports are that 1) knowledge about ARIA should be disseminated throughout clinical teams providing stroke care, 2) ARIA risk can be stratified by pretreatment markers of CAA and incorporated into risk-benefit discussions, 3) the suggestive link between elevated blood pressure and ARIA risk supports close adherence to hypertension guidelines, 4) concomitant anticoagulation may increase risk of symptomatic ARIA-H and therefore requires considerable caution, 5) particular vigilance is required to avoid administering thrombolytics to patients with ARIA-E presenting as a stroke mimic, which has resulted in several fatalities, and 6) in addition stopping antibody infusion, high-dose corticosteroids can be considered for treatment of severe ARIA. These vascular considerations will likely evolve with ongoing post-marketing data collection efforts.

Key findings

• Abstract Amyloid-related imaging abnormalities (ARIA) in the form of edema/effusions (ARIA-E) or hemorrhagic lesions (ARIA-H) are the most impactful adverse event associated with anti-amyloid immunotherapy for Alzheimer disease.

Why it matters

This review describes ARIA as the most impactful adverse event of anti-amyloid immunotherapy and discusses vascular issues such as CAA markers, anticoagulant and thrombolytic safety, and treatment of severe ARIA. It addresses risk management rather than curing or preventing Alzheimer's disease.

New to this subject? Start with our plain-English guide: Treatments →

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1093/geroni/igaf122.1009
• Original source →
• Free full text: Innovation in Aging →

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

@article{greenberg2025-74e40508,
  author  = {Greenberg, S.},
  title   = {{Vascular Considerations for Patients Receiving Amyloid Immunotherapy}},
  journal = {Innovation in Aging},
  year    = {2025},
  doi     = {10.1093/geroni/igaf122.1009},
  url     = {https://doi.org/10.1093/geroni/igaf122.1009}
}

Related studies in Treatments

• Vascular Considerations for Amyloid Immunotherapy Current neurology and neuroscience reports · 2022-10-21 · usefulness score 40/100
• Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer's disease Molecular neurodegeneration · 2024-10-21 · usefulness score 45/100
• Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities Alzheimer's & dementia : the journal of the Alzheimer's Association · 2013-04-11 · usefulness score 43/100
• Intravenous anti-Aβ immunotherapy acutely increases cerebral amyloid angiopathy and vascular damages in APOE4 mice bioRxiv · 2026-02-11 · usefulness score 16/100
• Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval The journal of prevention of Alzheimer's disease · 2023-01-01 · usefulness score 47/100
• Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities AJNR. American journal of neuroradiology · 2025-01-08 · usefulness score 41/100

Similar studies

• Immunotherapy for Alzheimer's disease 2014 · Disparities
• “Doctor, if it were you, which would you choose?”: Navigating personal preference questions in anti‐amyloid immunotherapy selection 2026 · Treatments
• Practical lessons from amyloid immunotherapy trials in Alzheimer disease 2012 · Treatments
• Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada 2026 · Treatments
• Determining eligibility for anti‐amyloid treatments using blood biomarkers 2025 · Biomarkers
• Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease 2025 · Health systems and care delivery

More on Treatments

• A review that covers this ground Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease Expert opinion on drug metabolism & toxicology · 2020-06-23 · usefulness score 39/100
• Newest in this subject Opposing Regulation of Tau Condensation by Phosphorylation Levels and Molecular Chaperone Interactions bioRxiv · 2026-10-30 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling Research Square · 2026-10-20 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Treatments →